Company intelligence / Profile preview

Valneva

Ownership: Public · VALN
Employees: ~700
Development stage: Commercial

Overview

Valneva has three commercial vaccines including IXIARO/JESPECT for Japanese encephalitis, DUKORAL for cholera, and IXCHIQ for chikungunya (approved by FDA in November 2023). The company also has several vaccines in development, including a Lyme disease vaccine in partnership with Pfizer planned for release around 2026.

Therapeutic areas: Infectious Diseases
Modalities: Vaccines
Industry: Biotech

Drug pipeline

25 assets

Japanese encephalitis vaccine

Approved

24 more assets in the full pipeline.

Partnerships

Pfizer (for Lyme disease vaccine)Emergent BioSolutions (for Zika vaccine)Hookipa

Financials

Market cap: $528.9M
Total revenue: $195.2M
Enterprise value: $628M

Beyond the preview

Go deeper on Valneva.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Valneva.